The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to raltegravir and impact the enzyme functions

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Reigadas, Sandrine ^a   Anies, Guerric ^a,d   Masquelier, Bernard ^a   Calmels, Christina ^b   Stuyver, Lieven J ^c   Parissi, Vincent ^b   Fleury, Herve ^a   Andreola, Marie Line ^b  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b University Victor Segalen   (France)

^c Virco BVBA   (Belgium)

^d CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; INTEGRASE; RALTEGRAVIR; TENOFOVIR DISOPROXIL; 2 PYRROLIDONE DERIVATIVE;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; ASSAY; CASE REPORT; CONTROLLED STUDY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME SUBSTRATE; EVOLUTION; GENE LOCUS; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; MOLECULAR CLONING; NONHUMAN; PHENOTYPE; STRUCTURAL GENE; VIRUS RESISTANCE; DRUG RESISTANCE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; METABOLISM; MISSENSE MUTATION; TREATMENT FAILURE;

DRUG RESISTANCE; HIV INFECTIONS; HIV INTEGRASE; HUMANS; INHIBITORY CONCENTRATION 50; MUTATION, MISSENSE; PYRROLIDINONES; TREATMENT FAILURE;

EID: 77956412031     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010311     Document Type: Article

References (31)

1. Asante-Appiah E, Skalka AM (1997) Molecular mechanisms in retrovirus DNA integration. Antiviral Res 36: 139-156.
2. Yang W, Steitz TA (1995) Recombining the structures of HIV integrase, RuvC and RNase H. Structure 3: 131-134.
3. Pommier Y, Johnson AA, Marchand C (2005) Integrase inhibitors to treat HIV/ AIDS. Nat Rev Drug Discov 4: 236-248.
4. Pannecouque C, Pluymers W, Van Maele B, Tetz V, Cherepanov P, et al. (2002) New class of HIV integrase inhibitors that block viral replication in cell culture. Curr Biol 12: 1169-1177.
5. Bonnenfant S, Thomas CM, Vita C, Subra F, Deprez E, et al. (2004) Styrylquinolines, integrase inhibitors acting prior to integration: a new mechanism of action for anti-integrase agents. J Virol 78: 5728-5736.
6. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, et al. (2000) Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287: 646-650.
7. Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, et al. (2006) Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 43: 509-515.
8. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, et al. (2007) Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369: 1261-1269.
9. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, et al. (2008) Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 359: 339-354.
10. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, et al. (2008) Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 359: 355-365.
11. Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, et al. (2009) Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev 11: 17-29.
12. Marinello J, Marchand C, Mott BT, Bain A, Thomas CJ, et al. (2008) Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 47: 9345-9354.
13. Delelis O, Malet I, Na L, Tchertanov L, Calvez V, et al. (2009) The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res 37: 1193-1201.
14. Wittkop L, Breilh D, Da Silva D, Duffau P, Mercie P, et al. (2009) Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort. J Antimicrob Chemother 63: 1251-1255.
15. Caumont AB, Jamieson GA, Pichuantes S, Nguyen AT, Litvak S, et al. (1996) Expression of functional HIV-1 integrase in the yeast Saccharomyces cerevisiae leads to the emergence of a lethal phenotype: potential use for inhibitor screening. Curr Genet 29: 503-510.
16. Faure A, Calmels C, Desjobert C, Castroviejo M, Caumont-Sarcos A, et al. (2005) HIV-1 integrase crosslinked oligomers are active in vitro. Nucleic Acids Res 33: 977-986.
17. Lesbats P, Metifiot M, Calmels C, Baranova S, Nevinsky G, et al. (2008) In vitro initial attachment of HIV-1 integrase to viral ends: control of the DNA specific interaction by the oligomerization state. Nucleic Acids Res 36: 7043-7058.
18. Moreau K, Faure C, Violot S, Verdier G, Ronfort C (2003) Mutations in the C-terminal domain of ALSV (Avian Leukemia and Sarcoma Viruses) integrase alter the concerted DNA integration process in vitro. Eur J Biochem 270: 4426-4438.
19. Canducci F, Sampaolo M, Marinozzi MC, Boeri E, Spagnuolo V, et al. (2009) Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS 23: 455-460.
20. Fransen S, Gupta S, Frantznell A, Petropoulos C, Huang W (2009) Impaired replication capacity segregates genetic pathways to raltegravir resistance. Antivir Ther 14 Suppl 1: A109.
21. de Soultrait VR, Lozach PY, Altmeyer R, Tarrago-Litvak L, Litvak S, et al. (2002) DNA aptamers derived from HIV-1 RNase H inhibitors are strong anti-integrase agents. J Mol Biol 324: 195-203.
22. Esposito D, Craigie R (1998) Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction. EMBO J 17: 5832-5843.
23. Alian A, Griner SL, Chiang V, Tsiang M, Jones G, et al. (2009) Catalytically-active complex of HIV-1 integrase with a viral DNA substrate binds anti-integrase drugs. Proc Natl Acad Sci U S A 106: 8192-8197.
24. De Luca L, Vistoli G, Pedretti A, Barreca ML, Chimirri A (2005) Molecular dynamics studies of the full-length integrase-DNA complex. Biochem Biophys Res Commun 336: 1010-1016.
25. Mouscadet JF, Arora R, Andre J, Lambry JC, Delelis O, et al. (2009) HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations. J Mol Recognit 22: 480-494.
26. Delelis O, Thierry S, Subra F, Simon F, Malet I, et al. (2010) Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob Agents Chemother 54: 491-501.
27. Buzon MJ, Dalmau J, Puertas MC, Puig J, Clotet B, et al. (2009) The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates. AIDS 24: 17-25.
28. Canducci F, Marinozzi MC, Sampaolo M, Boeri E, Spagnuolo V, et al. (2010) Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. J Antimicrob Chemother 65: 425-33.
29. Lataillade M, Chiarella J, Kozal MJ (2007) Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 12: 563-570.
30. Van Baelen K, Rondelez E, Van Eygen V, Arien K, Clynhens M, et al. (2009) A combined genotypic and phenotypic human immunodeficiency virus type 1 recombinant virus assay for the reverse transcriptase and integrase genes. J Virol Methods 161: 231-239.
31. Van Baelen K, Van Eygen V, Rondelez E, Stuyver LJ (2008) Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility. AIDS 22: 1877-1880.